The Company Helping Paralyzed People Move And Thrive Again - EP 64 Dave Marver

Onward’s core technology combines epidural spinal cord stimulation with a brain‑computer interface (BCI) to translate a patient’s movement intent into precise electrical pulses that re‑activate paralyzed limbs. The company’s ArcIM neurostimulator, already implanted in humans for eight years, works alongside a 64‑electrode cortical device that sits outside the dura, avoiding invasive brain penetration. Real‑world cases like Suzanne Edwards, who regained stepping ability, and Julie, whose blood‑pressure regulation dramatically improved, illustrate how thought‑driven control can move beyond novelty games to genuine functional recovery for spinal cord injury (SCI) patients.

Beyond locomotion, Onward’s platform targets autonomic dysfunctions that dominate daily life for many with SCI. Chronic low blood pressure, orthostatic intolerance, and bladder or bowel control issues often eclipse the desire to simply walk. By positioning leads at specific spinal segments, the system can modulate cardiovascular tone and sphincter function, delivering measurable quality‑of‑life gains. Clinicians note that stabilizing blood pressure alone can lift depressive symptoms and cognitive fog, underscoring the therapeutic breadth of neurostimulation beyond motor restoration.

Onward differentiates itself from hype‑driven BCI startups by leveraging clinically vetted hardware and a regulatory‑friendly pathway. The epidural BCI avoids subdural or penetrating implants, reducing infection risk and accelerating FDA clearance. The company remains agnostic about upstream BCI sources, maintaining collaborations with firms like Neuralink, Synchron, and Precision Neuro to ingest richer neural data when needed. With a med‑tech‑focused investor base and a pipeline slated for commercial launch within a few years, Onward positions its spinal‑BCI combo as a scalable, near‑term solution for the 300,000 Americans living with paralysis.